AI assistant
Sending…
KALA BIO, Inc. — Director's Dealing 2020
Mar 17, 2020
35091_dirs_2020-03-17_813b130d-bb29-44fe-b1cf-2e690b5e4bae.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2020-03-16
Reporting Person: Bazemore Todd (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-03-16 | Common Stock | P | 10000 | $5.75 | Acquired | 10000 | Direct |
More from KALA BIO, Inc.
Interim / Quarterly Report
2026
May 15
Annual Report
2026
Apr 15
Regulatory Filings
2026
Mar 17
Regulatory Filings
2026
Mar 17
Capital/Financing Update
2026
Mar 4
Board/Management Information
2026
Feb 20
Major Shareholding Notification
2026
Feb 17
Capital/Financing Update
2026
Feb 9
Director's Dealing
2026
Feb 9
Director's Dealing
2026
Feb 9